Table 4.
Retrospective studies evaluating the use of salvage ASCT in relapsed multiple myeloma
| Study | No. | ORR (%) | Median PFS (months) | Median OS (months) | TRM (%) |
|---|---|---|---|---|---|
| Shah et al. [111] | 44 | 90 | 12.3 | 31.7 | 2 |
| Jimenez-Zepaeda et al. [110] | 81 | 97 | 16.4 | 53 | 3 |
| Olin et al. [116] | 41 | 55 | 8.5 | 20.7 | 7 |
| Fenk et al. [114] | 55 | 75 | 14 | 52 | 5 |
| Alvares et al. [120] | 83 | — | 15.6 | 34.8 | — |
| Burzynski et al. [115] | 25 | 64 | 12 | 19 | 8 |
| Mehta et al. [133] | 42 | 81 | 12.5 | 32 | 10 |
| Eliece et al. [117] | 26 | 69 | 14.8 | 38.1 | 0 |
| Gonsalves et al. [107] | 98 | 86 | 10.3 | 33 | 4 |
| Yhim et al. [119] | 48 | — | 18 | 55.5 | — |
| Lemieux et al. [108] | 81 | 93 | 18 | 48 | 0 |
| Michaelis et al. [109] | 187 | — | 3-year PFS: 13% | 3-year OS: 46% | 2 |
TRM treatment-related mortality, ORR overall response rate, PFS progression-free survival, OS overall survival